Skip to main content
4BASEBIO PLC logo

4BASEBIO PLC — Investor Relations & Filings

Ticker · 4BB ISIN · GB00BMCLYF79 LEI · 213800E2DX9EAIUNCB30 IL Manufacturing
Open in API
Filings indexed 92 across all filing types
Latest filing 2024-11-15 Major Shareholding Noti…
Country GB United Kingdom
Listing IL 4BB

About 4BASEBIO PLC

https://www.4basebio.com/

4BASEBIO PLC is a biotechnology company specializing in the design and manufacturing of synthetic DNA for next-generation therapeutics and vaccines. The company provides high-purity, Good Manufacturing Practice (GMP) grade nucleic acid products, including its proprietary opDNA®, as a plasmid-free alternative to traditional methods. Its technology is engineered to accelerate development timelines, enhance safety, and improve manufacturing scalability for applications in genetic medicine, including mRNA vaccines, viral vector-based gene therapies, and gene editing. 4basebio's solutions aim to eliminate production bottlenecks and de-risk manufacturing for partners in the pharmaceutical and biotechnology sectors.

Recent filings

Filing Released Lang Actions
4basebio Plc - Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains structured fields detailing changes in voting rights percentages (e.g., 'Resulting situation on the date on which threshold was crossed or reached' showing a change from 4.19% to 3.47%). This format is characteristic of regulatory filings related to significant changes in share ownership, which corresponds to the definition of Major Shareholding Notification (MRQ). The document is a direct notification form, not an announcement of a report (RPA) or a general regulatory filing (RNS).
2024-11-15 English
4basebio Plc - Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains structured tables detailing 'NOTIFICATION OF MAJOR HOLDINGS'. It reports on the acquisition or disposal of voting rights and the resulting percentage of ownership crossing a threshold (29.9%). This format and content directly correspond to regulatory filings concerning changes in significant share ownership, which aligns with the definition for Major Shareholding Notification (MRQ).
2024-11-15 English
4basebio Plc - Appointment of Joint Corporate Broker
Regulatory Filings Classification · 1% confidence The document is a short press release dated November 14, 2024, announcing the 'Appointment of Joint Corporate Broker' (RBC Capital Markets joining Cavendish Capital Markets). This announcement concerns changes related to the company's advisory/brokerage structure, which falls under general corporate governance or management updates. It is not a full financial report (10-K, IR), an earnings release (ER), a dividend notice (DIV), or a director's dealing report (DIRS). Since it involves the appointment of key financial advisors/brokers, it is most closely related to Board/Management Information (MANG) or a general regulatory announcement. Given the specific nature of appointing a corporate broker, which is a significant corporate action affecting investor relations, MANG is the most appropriate fit among the specific categories, as it relates to the structure supporting the company's operations and investor engagement. It is too specific for the general RNS fallback.
2024-11-14 English
4basebio Plc - Completion of Strategic Investment
Share Issue/Capital Change Classification · 1% confidence The document announces the 'Completion of Strategic Investment' involving the issuance of new shares ('Issuance Shares') and the purchase of existing shares ('Sale Shares'), resulting in changes to significant shareholdings and director appointments/resignations. Key phrases include 'Director Dealing, Issue of Equity and Admission to Trading' and 'Director Appointment and Board Changes'. The issuance of new shares and the resulting change in total voting rights strongly indicate a capital structure change or share transaction. Since the core event is the issuance of new shares as part of a financing/investment deal, 'Capital/Financing Update' (CAP) is a strong candidate. However, the document also explicitly details director appointments and changes, which points towards 'Board/Management Information' (MANG). Furthermore, the transaction involves the purchase of shares from directors and a significant change in ownership structure, which touches upon insider dealing and major shareholding notifications. Given the dual focus on a major financing event (Strategic Investment via Issuance) and subsequent board changes, 'CAP' (Capital/Financing Update) is the most encompassing category for the primary financial action described, although 'MANG' is also highly relevant due to the director changes. Since the investment involves the issuance of equity to raise capital, CAP is prioritized over MANG, which usually focuses solely on personnel changes without a major capital event attached. The document is a full announcement, not just a notification of publication, so RPA/RNS is incorrect.
2024-11-12 English
4basebio Plc - Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Standard form for notification of major holdings' concerning 4BASEBIO PLC. This form is used to report changes in significant share ownership (crossing thresholds) by an individual or entity. This directly corresponds to the definition of a Major Shareholding Notification. The document details the shareholder (Sparta AG), the resulting holding percentage (10.556002%), and the date the threshold was crossed (30-Sep-2024). This fits the 'Major Shareholding Notification' category (MRQ) much better than the general 'Regulatory Filings' (RNS) or 'Director's Dealing' (DIRS), as it specifically concerns ownership thresholds.
2024-10-03 English
4basebio Plc - Half-year Report
Interim / Quarterly Report Classification · 1% confidence The document is a 'Half-year Report' for 4basebio PLC for the period ended 30 June 2024. It contains comprehensive financial statements, including a consolidated statement of profit or loss, balance sheet, and cash flow analysis, along with management's discussion and analysis (Chairman's Statement, Operational Review, and Financial Review). As it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2024
2024-09-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.